Role of mGluR5 positive allosteric modulators in schizophrenia
mGluR5 正变构调节剂在精神分裂症中的作用
基本信息
- 批准号:8141400
- 负责人:
- 金额:$ 4.68万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-07-01 至 2012-06-30
- 项目状态:已结题
- 来源:
- 关键词:AcousticsAddressAgonistAllosteric SiteAlzheimer&aposs DiseaseAmphetaminesAnimal ModelAnimalsAntipsychotic AgentsAreaBehavioralBehavioral AssayBindingBinding SitesBiological ModelsBrainChemicalsChemosensitizationCognition DisordersCognitiveCognitive deficitsCoupledDataDevelopmentDiseaseEpilepsyExhibitsGlutamatesHippocampus (Brain)Huntington DiseaseImpaired cognitionImpairmentIndividualLeadLigandsLiteratureMK801MeasuresMediatingMental disordersMetabotropic Glutamate ReceptorsMethodsMitogen-Activated Protein KinasesModelingMolecularMutationParkinson DiseasePatientsPerformancePharmaceutical PreparationsPharmacologyPhosphorylationPhysiologicalPropertyRegulationResearchRodent ModelRoleSchizophreniaSeriesSignal TransductionSiteSite-Directed MutagenesisSymptomsTestingTherapeuticTherapeutic AgentsToxic effectWithdrawalbasecognitive functiondisease characteristicflexibilityfunctional outcomesimprovedin vitro Assayin vivomutantneuropsychiatryneurotransmissionnovelnovel strategiesprepulse inhibitionprototypepublic health relevanceradioligandreceptorresponsescaffoldtheoriestool
项目摘要
DESCRIPTION (provided by applicant): The purpose of this project is to gain a deeper understanding of allosteric modulation of the metabotropic glutamate receptor subtype 5 (mGluRS), and the role of the receptor in psychiatric disorders, such as schizophrenia. It is hoped that this research will add to a growing body of literature that will lead to more effective psychiatric medication, and thus improved functional outcomes for patients. This project will address two related objectives. First, a novel class of positive allosteric modulators (PAMs) of mGluR5 will be assessed to test the hypothesis that these compounds are binding to a novel site on the receptor. Second, the efficacy of these mGluRS PAMs will be evaluated in animal models to test the hypothesis that the compounds will have antipsychotic and cognitive-enhancing activity. The glutamate hypothesis of schizophrenia states that one cause of the positive and negative symptoms as well as cognitive deficits characteristic of the disease may be a change in signaling through the /V-methyl-D-aspartatereceptor (NMDAR). Direct enhancement of NMDAR function has been found to ameliorate schizophrenic symptoms but has toxic effects. Studies have shown that mGluRS and the NMDAR are closely coupled signaling partners, and activation of mGluRS can potentiate NMDAR current in the hippocampus. Thus activating mGluRS using PAMs can indirectly enhance NMDAR function and consequently ameliorate symptoms of schizophrenia. For the first aim of this project, the domains of mGluRS that are necessary for the function of the novel PAMs will be explored using site-directed mutagenesis. Mutant receptors that inhibit the function of certain mGluRS modulators will be used to determine the effects of the mutants on the actions of the novel compounds. Pharmacological methods based on classical receptor theory will also be used to determine whether the PAMs can compete with ligands that interact with the previously characterized MPEP site. Specifically, Schild analysis will determine whether the neutral allosteric ligand 5MPEP will competitively block the actions of the novel PAMs. For the second aim, behavioral assays will be conducted to establish the effects of these novel compounds. To evaluate antipsychotic efficacy, the ability of compounds to reverse amphetamine-induced hyperlocomotion and amphetamine-induced disruption of prepulse inhibition of the acoustic startle response (PPI) will be investigated. Next, the ability of the PAMs to reverse MK801-induced deficits in attentional set-shifting as a measure of cognitive flexibility will be studied. Public Health Relevance: Current treatment for schizophrenia is not sufficient to treat all symptoms of the disorder, especially the negative symptoms, (i.e. withdrawal) and cognitive deficits. This research is taking a novel pharmacological approach to address this problem, and will focus on the mGluRS receptor in the brain that seems to be involved in regulation of disrupted neurotransmission that leads to schizophrenic symptoms.
描述(申请人提供):本项目的目的是更深入地了解代谢性谷氨酸受体亚型5(MGluRs)的变构调节,以及该受体在精神障碍(如精神分裂症)中的作用。人们希望这项研究将增加越来越多的文献,从而导致更有效的精神药物治疗,从而改善患者的功能结果。该项目将涉及两个相关目标。首先,将评估一类新型的mGluR5正变构调节剂(PAM),以检验这些化合物与受体上一个新的位点结合的假设。其次,这些mGluRs PAM的有效性将在动物模型中进行评估,以检验化合物将具有抗精神病和增强认知活性的假设。精神分裂症的谷氨酸假说认为,精神分裂症阳性和阴性症状以及认知缺陷的一个原因可能是通过/V-甲基-D-天冬氨酸受体(NMDAR)的信号变化。NMDAR功能的直接增强被发现可以改善精神分裂症的症状,但也有毒性作用。研究表明,mGluRs和NMDAR是紧密耦合的信号伙伴,激活mGluRs可以增强海马区的NMDAR电流。因此,使用PAM激活mGluRs可以间接增强NMDAR功能,从而改善精神分裂症的症状。为了这个项目的第一个目标,将使用定点突变来探索新型PAM功能所必需的mGluR结构域。抑制某些mGluRs调节剂功能的突变受体将被用来确定突变对新化合物作用的影响。基于经典受体理论的药理学方法也将被用来确定PAM是否能够与与先前描述的MPEP位点相互作用的配体竞争。具体地说,SChild分析将确定中性变构配体5MPEP是否会竞争性地阻断新型PAM的作用。对于第二个目标,将进行行为分析,以确定这些新化合物的影响。为了评估抗精神病药物的疗效,将研究化合物逆转苯丙胺诱导的多动和苯丙胺诱导的脉冲前抑制声惊厥反应(PPI)的破坏的能力。接下来,将研究PAM逆转MK801诱导的注意定势转移缺陷的能力,作为一种认知灵活性的衡量标准。公共卫生相关性:目前对精神分裂症的治疗不足以治疗该疾病的所有症状,特别是阴性症状(即戒断)和认知缺陷。这项研究正在采取一种新的药理学方法来解决这个问题,并将重点放在大脑中的mGluRs受体,该受体似乎参与调节导致精神分裂症症状的神经传递中断。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alexis Shea Hammond其他文献
Alexis Shea Hammond的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alexis Shea Hammond', 18)}}的其他基金
Role of mGluR5 positive allosteric modulators in schizophrenia
mGluR5 正变构调节剂在精神分裂症中的作用
- 批准号:
7870298 - 财政年份:2009
- 资助金额:
$ 4.68万 - 项目类别:
Role of mGluR5 positive allosteric modulators in schizophrenia
mGluR5 正变构调节剂在精神分裂症中的作用
- 批准号:
7678180 - 财政年份:2009
- 资助金额:
$ 4.68万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 4.68万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 4.68万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 4.68万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 4.68万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 4.68万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 4.68万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 4.68万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 4.68万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 4.68万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 4.68万 - 项目类别:
Research Grant